Advertisement

Tijdschrift voor Kindergeneeskunde

, Volume 78, Issue 2, pp 73–77 | Cite as

Anemie, trombocytopenie en hepatosplenomegalie: de ziekte van Gaucher

  • M.H. de Ru
  • F.A. Wijburg
  • J.M.F.G. Aerts
  • E.D.M. Post
  • C.E.M. Hollak
Article

Samenvatting

De ziekte van Gaucher is een zeldzame autosomaal recessief erfelijke lysosomale stapelingsziekte die wordt veroorzaakt door deficiëntie van het lysosomale enzym glucocerebrosidase. Klinische verschijnselen treden op door stapeling van glucosylceramide, het natuurlijk substraat van het deficiënte enzym. De ziekte kent drie varianten: Gaucher type 1 wordt gekenmerkt door anemie, trombocytopenie, hepatosplenomegalie en botafwijkingen; bij de typen 2 en 3 is er tevens sprake van progressieve neurologische verschijnselen. Men spreekt ook wel van de nonneuronopathische vorm versus de neuronopathische vormen van de ziekte. De ziekte van Gaucher type 1 is goed behandelbaar met enzymvervangende therapie en, in sommige omstandigheden, met substraatreductietherapie. Het ziektebeeld wordt geïllustreerd aan de hand van een casus.

Summary

Gaucher disease is a rare autosomal recessive lysosomal storage disorder, due to a deficiency of the lysosomal enzyme glucocerebrosidase. Accumulation of its substrate in macrophages, glucosylceramide, leads to the clinical manifestations of the disorder. Three clinical subtypes are identified. Type-1 Gaucher disease is characterized by the presence of anemia, thrombocytopenia, hepatosplenomegaly and bone abnormalities. Type-2 and type-3 disease are characterized by the presence of primary neurologic disease (non-neuronopathic form versus the neuronopathic forms). Treatment modalities approved for type-1 Gaucher disease are enzyme replacement therapy and substrate reduction therapy. The disease will be illustrated by a case report.

Literatuur

  1. 1.
    Hollak C, Boot R, Poorthuis B, Aerts J. Van gen naar ziekte; de ziekte van Gaucher. Ned Tijdschr Geneeskd. 2005;149:2163–6.PubMedGoogle Scholar
  2. 2.
    Grabowski G. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372: 1263–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Martins A, Valadares E, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl):S10–8.PubMedGoogle Scholar
  4. 4.
    Scriver C, Beaudet A, Sly W,Valle D. The metabolic and molecular basis of inherited disease, 8th ed. New York: Mc Graw-Hill, 2001.Google Scholar
  5. 5.
    Barton N, Brady R, Dambrosia J, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324:1464–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Hollak C, Aerts J, Oers M van. Treatment of Gaucher’s disease. N Engl J Med. 1993;328:1565–6.PubMedGoogle Scholar
  7. 7.
    Elstein D, Hollak C, Aerts J, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Aerts J, Hollak C, Boot R, et al. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Boot R, Verhoek M, Fost M de, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Boot R, Breemen M van,Wegdam W, et al. Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics. 2009;6:411–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Hillborg P. Gaucher’s disease in Norrbotten. Nord Med. 1959;61:303–6.PubMedGoogle Scholar
  12. 12.
    Biegstraaten M, Schaik I van, Aerts J, Hollak C. ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31:337–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Davies E, Surtees R, DeVille C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis. 2007;30:768–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Hollak CE, Fost M de, Dussen L van, et al. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose – response relationships. Expert Opin Pharmacother. 2009;10: 2641–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Andersson H, Kaplan P, Kacena K, Yee J. Eightyear clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122:1182–90.CrossRefPubMedGoogle Scholar
  16. 16.
    Cox-Brinkman J, Breemen M van, Maldegem B van, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745–52.CrossRefPubMedGoogle Scholar

Copyright information

© Bohn, Stafleu van Loghum 2010

Authors and Affiliations

  • M.H. de Ru
    • 1
  • F.A. Wijburg
    • 1
  • J.M.F.G. Aerts
    • 2
  • E.D.M. Post
    • 3
  • C.E.M. Hollak
    • 4
  1. 1.
  2. 2.afdeling Medische BiochemieAMCAmsterdamThe Nederlands
  3. 3.St. Antonius ZiekenhuisNieuwegein/UtrechtThe Nederlands
  4. 4.afdeling Interne Geneeskunde, Endocrinologie en MetabolismeAMC, Amsterdam en Lysosome Center ‘Sphinx’AmsterdamThe Nederlands

Personalised recommendations